Sanara Med Tech Inc. SMTI
We take great care to ensure that the data presented and summarized in this overview for Sanara MedTech Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMTI
View all-
Black Rock Inc. New York, NY197KShares$7.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA173KShares$6.29 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA88.3KShares$3.21 Million0.0% of portfolio
-
State Street Corp Boston, MA58.7KShares$2.13 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL40.5KShares$1.47 Million0.0% of portfolio
-
Janney Montgomery Scott LLC32.8KShares$1.19 Million0.0% of portfolio
-
Royal Bank Of Canada Toronto, A626.4KShares$960,6110.0% of portfolio
-
North Run Capital, LP Wellesley, MA24KShares$872,1602.54% of portfolio
-
Pensionmark Financial Group, LLC Santa Barbara, CA21.1KShares$767,2100.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il20.5KShares$744,7150.0% of portfolio
Latest Institutional Activity in SMTI
Top Purchases
Top Sells
About SMTI
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Insider Transactions at SMTI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 11
2024
|
Keith G Myers Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,975
+50.0%
|
-
|
Jun 12
2024
|
Eric D Major Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,440
+36.02%
|
-
|
Jun 12
2024
|
Robert Andrew De Sutter Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,932
+16.81%
|
-
|
Jun 12
2024
|
Ronald T Nixon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,812
+16.06%
|
-
|
Jun 12
2024
|
Ann Beal Salamone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,949
+12.91%
|
-
|
Jun 12
2024
|
James W Stuckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,440
+0.41%
|
-
|
Jun 12
2024
|
Eric D Tanzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,768
+21.13%
|
-
|
Jun 12
2024
|
Roszell Mack Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,604
+21.57%
|
-
|
Jun 12
2024
|
Sara N Ortwein Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,440
+16.41%
|
-
|
Apr 15
2024
|
Jacob A. Waldrop Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,101
+50.0%
|
-
|
Mar 07
2024
|
Michael D. Mc Neil Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,650
+15.17%
|
-
|
Mar 07
2024
|
Zachary B. Fleming Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,693
+20.62%
|
-
|
Mar 01
2024
|
Zachary B. Fleming Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,716
-2.29%
|
$65,208
$38.96 P/Share
|
Mar 01
2024
|
Michael D. Mc Neil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,286
-2.88%
|
$48,868
$38.96 P/Share
|
Feb 01
2024
|
Zachary B. Fleming Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
427
-1.11%
|
$14,091
$33.72 P/Share
|
Feb 01
2024
|
Michael D. Mc Neil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
391
-1.7%
|
$12,903
$33.72 P/Share
|
Jan 01
2024
|
Zachary B. Fleming Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,255
-3.17%
|
$51,455
$41.1 P/Share
|
Sep 21
2023
|
Zachary B. Fleming Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-1.7%
|
$25,308
$37.19 P/Share
|
Jun 01
2023
|
Roszell Mack Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,802
+22.78%
|
-
|
Jun 01
2023
|
Ann Beal Salamone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,402
+12.41%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 57.8K shares |
---|
Payment of exercise price or tax liability | 5.08K shares |
---|